|
Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes
|
Aug 2017
|
Leukemia
|
|
|
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
|
Jan 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.
|
Jan 2019
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes.
|
Jun 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Therapy-related Myelodysplastic Syndromes Deserve Specific Diagnostic Sub-Classification and Risk-Stratification-An Approach to Classification of Patients With t-MDS
|
Jun 2020
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Whole exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia
|
Dec 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?
|
Jan 2021
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
|
Mar 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Immunomodulation With Pomalidomide at Early Lymphocyte Recovery After Induction Chemotherapy in Newly Diagnosed AML and High-Risk MDS
|
Jun 2020
|
Leukemia
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry
|
Sep 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
